These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19707399)

  • 21. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
    Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews.
    Visacri MB; Ribeiro MC; Komoda DS; Duarte BKL; Correa CRS; Maia FOM; Alves DFDS
    Value Health Reg Issues; 2024 Sep; 43():100998. PubMed ID: 38718736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bortezomib in the front-line treatment of multiple myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
    Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of multiple myeloma in the elderly: realities and hopes.
    De La Rubia J; Sanz MA
    Leuk Lymphoma; 2011 Jan; 52(1):9-14. PubMed ID: 21077740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant.
    Sacchi S; Marcheselli R; Lazzaro A; Morabito F; Fragasso A; Di Renzo N; Balleari E; Neri S; Quarta G; Ferrara R; Vigliotti ML; Polimeno G; Musto P; Consoli U; Zoboli A; Buda G; Pastorini A; Masini L
    Leuk Lymphoma; 2011 Oct; 52(10):1942-8. PubMed ID: 21663513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple myeloma: treatment evolution.
    San Miguel JF; Mateos MV; Ocio E; Garcia-Sanz R
    Hematology; 2012 Apr; 17 Suppl 1():S3-6. PubMed ID: 22507766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
    Gay F; Magarotto V; Crippa C; Pescosta N; Guglielmelli T; Cavallo F; Pezzatti S; Ferrari S; Liberati AM; Oliva S; Patriarca F; Offidani M; Omedé P; Montefusco V; Petrucci MT; Giuliani N; Passera R; Pietrantuono G; Boccadoro M; Corradini P; Palumbo A
    Blood; 2013 Aug; 122(8):1376-83. PubMed ID: 23775712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis.
    Kapoor P; Rajkumar SV; Dispenzieri A; Gertz MA; Lacy MQ; Dingli D; Mikhael JR; Roy V; Kyle RA; Greipp PR; Kumar S; Mandrekar SJ
    Leukemia; 2011 Apr; 25(4):689-96. PubMed ID: 21233832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
    Palumbo A; Bringhen S; Rossi D; Cavalli M; Larocca A; Ria R; Offidani M; Patriarca F; Nozzoli C; Guglielmelli T; Benevolo G; Callea V; Baldini L; Morabito F; Grasso M; Leonardi G; Rizzo M; Falcone AP; Gottardi D; Montefusco V; Musto P; Petrucci MT; Ciccone G; Boccadoro M
    J Clin Oncol; 2010 Dec; 28(34):5101-9. PubMed ID: 20940200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
    Palumbo A; Bringhen S; Caravita T; Merla E; Capparella V; Callea V; Cangialosi C; Grasso M; Rossini F; Galli M; Catalano L; Zamagni E; Petrucci MT; De Stefano V; Ceccarelli M; Ambrosini MT; Avonto I; Falco P; Ciccone G; Liberati AM; Musto P; Boccadoro M;
    Lancet; 2006 Mar; 367(9513):825-31. PubMed ID: 16530576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
    Benboubker L; Dimopoulos MA; Dispenzieri A; Catalano J; Belch AR; Cavo M; Pinto A; Weisel K; Ludwig H; Bahlis N; Banos A; Tiab M; Delforge M; Cavenagh J; Geraldes C; Lee JJ; Chen C; Oriol A; de la Rubia J; Qiu L; White DJ; Binder D; Anderson K; Fermand JP; Moreau P; Attal M; Knight R; Chen G; Van Oostendorp J; Jacques C; Ervin-Haynes A; Avet-Loiseau H; Hulin C; Facon T;
    N Engl J Med; 2014 Sep; 371(10):906-17. PubMed ID: 25184863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New treatments for multiple myeloma.
    Richardson PG; Schlossman R; Hideshima T; Anderson KC
    Oncology (Williston Park); 2005 Dec; 19(14):1781-92; discussion 1792, 1795-7. PubMed ID: 16506632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
    Verelst SG; Termorshuizen F; Uyl-de Groot CA; Schaafsma MR; Ammerlaan AH; Wittebol S; Sinnige HA; Zweegman S; van Marwijk Kooy M; van der Griend R; Lokhorst HM; Sonneveld P; Wijermans PW;
    Ann Hematol; 2011 Dec; 90(12):1427-39. PubMed ID: 21472373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [First-line treatment of multiple myeloma].
    Breitkreutz I; Raab M; Goldschmidt H
    Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New concept of the treatment in elderly patients with multiple myeloma].
    Bila J; Gotić M; Mihaljević B
    Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():110-5. PubMed ID: 22352192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of disease- and treatment-related complications in patients with multiple myeloma.
    Gay F; Palumbo A
    Med Oncol; 2010 Jun; 27 Suppl 1():S43-52. PubMed ID: 20467920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
    Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
    Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.